Log In Sign up
The largest database of trusted experimental protocols

N high sensitivity crp

Manufactured by Siemens
Visit Supplier
Sourced in Germany, United States

The N High Sensitivity CRP is a lab equipment product from Siemens. It is designed for the quantitative determination of C-reactive protein (CRP) in human serum and plasma.

Automatically generated - may contain errors

Lab products found in correlation

Sta r instrument, by Diagnostica Stago (1 mentions) Vacutainer, by BD (1 mentions) Ortho vitros clinical chemistry system 950irc instrument, by Johnson & Johnson (1 mentions) Quantikine hs human il 6 immunoassay, by R&D Systems (1 mentions) N antiserum to human fibrinogen, by Siemens (1 mentions) Elecsys il 6 kit, by Roche (1 mentions) Cobas e411, by Roche (1 mentions) Sta fibrinogen, by Diagnostica Stago (1 mentions) Sta liatest d di, by Diagnostica Stago (1 mentions) Sta r analyser, by Diagnostica Stago (1 mentions) Ca 7000, by Sysmex (1 mentions)

15 protocols using n high sensitivity crp

1

Cardiovascular Risk Factors Assessment

Check if the same lab product or an alternative is used in the 5 most similar protocols
A number of evaluations were performed as part of MESA Visit 1. HsCRP was measured using a BNII nephelometer (N-High Sensitivity CRP; Dade Behring Inc, Deerfield, IL). Sociodemographic characteristics, family history of CHD, tobacco use, and medication use were self-reported using a standardized questionnaire. Resting blood pressure and waist circumference were measured following standardized protocols [18 (link)]. Fasting levels of total and high density lipoprotein (HDL) cholesterol, and blood glucose were measured at the MESA central laboratory at the University of Minnesota.
Cainzos-Achirica M., Miedema M.D., McEvoy J.W., Cushman M., Dardari Z., Greenland P., Nasir K., Budoff M.J., Al-Mallah M.H., Yeboah J., Blumenthal R.S., Comin-Colet J, & Blaha M.J. (2018). The Prognostic Value of High Sensitivity C-Reactive Protein in a Multi-Ethnic Population After More Than 10 Years of Follow-Up: The Multi-Ethnic Study of Atherosclerosis (MESA). International journal of cardiology, 264, 158-164.
+ Open protocol
+ Expand
2

Inflammatory Biomarker Measurement Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
To obtain the inflammatory profile, 15 mL of blood was taken via vein puncture, always in the morning. It was stored in a tube containing protease inhibitor and EDTA, then centrifuged at 3000 rpm for 15 min at 4 °C. The resulting plasma was transferred to micro centrifuge tubes (1.5 mL) and stored at −80 °C. This sample was later sent for analysis of Interleukin-6 (IL-6), Interleukin-10 (IL-10), Cortisol, and C-reactive Protein (CRP).
IL-6, IL-10, and cortisol were measured by the Enzyme-Linked Immuno-Sobent Assay (ELISA) method and Chemiluminescent Competitive Immunoassay following the manufacturer’s recommendations. The quantitative determination of CRP was performed by nephelometry (Dade-Behring N High Sensitivity CRP).
Corrêa F.I., Souza P.H., Uehara L., Ritti-Dias R.M., Oliveira da Silva G., Segheto W., Pacheco-Barrios K., Fregni F, & Corrêa J.C. (2022). Transcutaneous Auricular Vagus Nerve Stimulation Improves Inflammation but Does Not Interfere with Cardiac Modulation and Clinical Symptoms of Individuals with COVID-19: A Randomized Clinical Trial. Life, 12(10), 1644.
+ Open protocol
+ Expand
3

Biomarker Analysis in Coagulation Disorders

Check if the same lab product or an alternative is used in the 5 most similar protocols
Baseline and follow‐up blood samples were analyzed in cases and controls using the following methods: fibrinogen (clot‐rate assay, STA‐R instrument, Diagnostica Stago, Parsippany, NJ, USA), factor VIII and IX activity (clotting time on mixing with factor VIII or IX deficient plasma using STA‐Deficient VIII or IX; STA‐R instrument, Diagnostica Stago), von Willebrand factor, antithrombin and D‐dimer (immunoturbidometric or colorimetric assays, Liatest von Willebrand factor, Liatest D‐Di, Stachrom ATIII; STA‐R instrument, Diagnostica Stago), PAI‐1, PAP and prothrombin antigen (in‐house immunoassays),12, 13 prothrombin fragment 1.2 (ELISA, Dade Behring, Marburg, Germany), protein C antigen, free and total protein S antigen (Asserachrom ELISA, Diagnostica Stago), CRP (nephelometry, N High Sensitivity CRP, Dade‐Behring, Deerfield, IL, USA). Distributions of each biomarker were examined blind to case control status. Analytical outliers were defined based on knowledge of the biology and excluded from analysis as follows: factor VIIIc or prothrombin antigen <10%, fragment 1.2 > 7.2 nmol/L (>3 SD above the mean), PAI‐1 > 70 ng/mL.14
Cushman M., Larson J.C., Rosendaal F.R., Heckbert S.R., Curb J.D., Phillips L.S., Baird A.E., Eaton C.B, & Stafford R.S. (2018). Biomarkers, menopausal hormone therapy and risk of venous thrombosis: The Women's Health Initiative. Research and Practice in Thrombosis and Haemostasis, 2(2), 310-319.
+ Open protocol
+ Expand
4

Comprehensive Lipid and Inflammatory Biomarker Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
Fasting blood samples were collected in the early morning with patients in the supine position. Routine laboratory parameters were measured on a daily basis as previously described[18 (link)]. The lipoproteins were separated using a combined ultracentrifugation–precipitation method (β-quantification). Cholesterol and triglycerides were measured with enzymatic reagents from WAKO (Neuss, Germany) on a WAKO 30 R analyser. Apolipoproteins A-I, and B were measured by turbidimetry (Rolf-Greiner Biochemica, Flacht, Germany). Creatinine was measured with the Jaffé method on a Hitachi 717 analyzer (Roche Diagnostics, Mannheim, Germany). The CRP concentrations were determined using immunonephelometry (N High Sensitivity CRP, Dade Behring, Marburg, Germany). Total PCSK9 was measured using the Quantikine Human PCSK9 sandwich immunoassay (R&D, Minneapolis, MN, USA).
Rogacev K.S., Heine G.H., Silbernagel G., Kleber M.E., Seiler S., Emrich I., Lennartz S., Werner C., Zawada A.M., Fliser D., Böhm M., März W., Scharnagl H, & Laufs U. (2016). PCSK9 Plasma Concentrations Are Independent of GFR and Do Not Predict Cardiovascular Events in Patients with Decreased GFR. PLoS ONE, 11(1), e0146920.
+ Open protocol
+ Expand
5

Metabolic Profile Characterization

Check if the same lab product or an alternative is used in the 5 most similar protocols
Total and high-density lipoprotein (HDL) cholesterol, triglycerides, and glucose levels were measured from blood samples obtained after a 12-h fast. Low-density lipoprotein cholesterol was calculated by the Friedewald equation. Diabetes was defined as fasting glucose >125 mg/dl or use of hypoglycemic medication. C-reactive protein (CRP) was quantified by a high-sensitivity assay (N-High-Sensitivity CRP; Dade Behring, Deerfield, IL; inter-assay coefficient of variation: 2.1–5.7%).
Garg P.K., McClelland R.L., Jenny N.S., Criqui M.H., Greenland P., Rosenson R.S., Siscovick D.S., Jorgensen N, & Cushman M. (2015). Lipoprotein-Associated Phospholipase A2 and Risk of Incident Cardiovascular Disease in a Multi-Ethnic Cohort: The Multi Ethnic Study of Atherosclerosis. Atherosclerosis, 241(1), 176-182.
+ Open protocol
+ Expand
6

Measurement of High-Sensitivity C-Reactive Protein

Check if the same lab product or an alternative is used in the 5 most similar protocols
hsCRP was measured using the BNII nephelometer (N High Sensitivity CRP; Dade Behring Inc., Deerfield, Illinois) at the Laboratory for Clinical Biochemistry Research (University of Vermont, Burlington, Vermont). Analytical intra-assay coefficient of variations ranged from 2.3% to 4.4%, and inter-assay coefficient of variation ranged from 2.1% to 5.7% with a detection level of 0.18 mg/L.
Yeboah J., Polonsky T.S., Young R., McClelland R.L., Delaney J.C., Dawood F., Blaha M.J., Miedema M.D., Sibley C.T., Carr J.J., Burke G.L., Goff DC J.r., Psaty B.M., Greenland P, & Herrington D.M. (2015). Utility of Non-Traditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 ACC/AHA Cholesterol Guidelines. Circulation, 132(10), 916-922.
+ Open protocol
+ Expand
7

Ranolazine Effects on Systemic Inflammation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human samples were analyzed for CRP in patients undergoing ranolazine treatment within a previous study (44 (link)). Briefly, 51 patients aged between 32 and 65 y were included in a chronic phase of CAD at least 12 mo after acute myocardial infarction. All patients were treated with β-blockers, antiplatelet therapy, angiotensin-converting inhibitors or sartans, and statins. The therapy was not changed at least 6 wk prior to inclusion and during the study. In this double-blind study, patients were randomized to ranolazine 375 mg twice daily for the first 4 wk and 500 mg twice daily for 8 wk or to control treatment. Baseline patient characteristics including age, body mass index, cholesterol, high-density lipoprotein, LDL, and triglyceride levels can be found in SI Appendix, Table 1. Blood was drawn before and after 12 wk of treatment. High-sensitivity CRP was measured with a fully automated, latex-enhanced nephelometric immunoassay (N High Sensitivity CRP; Dade Behring).
Lenz M., Salzmann M., Ciotu C.I., Kaun C., Krychtiuk K.A., Rehberger Likozar A., Sebestjen M., Goederle L., Rauscher S., Krivaja Z., Binder C.J., Huber K., Hengstenberg C., Podesser B.K., Fischer M.J., Wojta J., Hohensinner P.J, & Speidl W.S. (2022). Pharmacologic modulation of intracellular Na+ concentration with ranolazine impacts inflammatory response in humans and mice. Proceedings of the National Academy of Sciences of the United States of America, 119(29), e2207020119.
+ Open protocol
+ Expand
8

Citrate-Anticoagulated Blood Sampling

Check if the same lab product or an alternative is used in the 5 most similar protocols
Blood samples were obtained using antecubital venipuncture with minimal compression and a 21 G needle. At each sampling time (baseline and 21 days after treatment withdrawal), the first 3 mL of blood were discarded and then 21 plastic tubes with 0.109 M trisodium citrate (Vacutainer®, BD Biosciences, Erembodegem, Belgium) were filled. The samples were immediately sent to the laboratory, which performed testing for hs-CRP (N High Sensitivity CRP, Dade Behring®; normal range: <5 mg/L) on a Behring Nephelometer II System and for DD (Acute Care™ D-dimer test pack, Siemens Healthcare Diagnostics, Newark, DE, USA; normal range: <500 µg/L).
Jara-Palomares L., Solier-Lopez A., Elias-Hernandez T., Asensio-Cruz M.I., Blasco-Esquivias I., Sanchez-Lopez V., de la Borbolla M.R., Arellano-Orden E., Suarez-Valdivia L., Marin-Romero S., Marin-Barrera L., Ruiz-Garcia A., Montero-Romero E., Navarro-Herrero S., Lopez-Campos J.L., Serrano-Gotarredona M.P., Praena-Fernandez J.M., Sanchez-Diaz J.M, & Otero-Candelera R. (2018). D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis. British Journal of Cancer, 119(8), 915-921.
+ Open protocol
+ Expand
9

Biomarker Measurement in Clinical Study

Check if the same lab product or an alternative is used in the 5 most similar protocols
Blood samples were collected, centrifuged, and serum and plasma was separated and shipped overnight on ice packs to the Laboratory for Clinical Biochemistry Research at the University of Vermont. High sensitivity CRP was analyzed by particle-enhanced immunonephelometry using the BNII nephelometer according to the manufacturer’s instructions (N High Sensitivity CRP; Dade Behring Inc., Deerfield, IL); the interassay coefficients of variation (CV) were 2.1%–5.7%. Albumin and glucose were measured in serum by colorimetric reflectance spectrophotometry using the Ortho Vitros Clinical Chemistry System 950IRC instrument (Johnson & Johnson Clinical Diagnostics; Rochester, NY); the CV was < 5% for albumin and 1% for glucose.
Complete blood counts were performed the day after sample collection using a Beckman Coulter LH 755 Hematology Workcell (Beckman Coulter, Incorporated; Fullerton, California); CVs of 5% and 10% for WBC and PLTC, respectively, were considered acceptable. Albumin, WBC, and PLTC were measured among consecutive individuals as part of an ancillary study that began after enrollment had started, resulting in 19,393 participants with serum albumin measured, 18,334 with WBC information, and 17,850 with PLTC measured.
Olson N.C., Cushman M., Lutsey P.L., McClure L.A., Judd S., Tracy R.P., Folsom A.R, & Zakai N.A. (2014). Inflammation Markers and Incident Venous Thromboembolism: the REasons for Geographic And Racial Differences in Stroke (REGARDS) Cohort. Journal of thrombosis and haemostasis : JTH, 12(12), 1993-2001.
+ Open protocol
+ Expand
10

Inflammatory Biomarker Measurement in Cardiovascular Research

Check if the same lab product or an alternative is used in the 5 most similar protocols
Serum hsCRP was measured using a high‐sensitivity assay (N‐High‐Sensitivity CRP; Dade Behring, Deerfield, IL) (intra‐assay coefficient of variation [CV] ranged from 2.3% to 4.4% and the interassay CV ranged from 2.1% to 5.7%). IL‐6 was measured by ultrasensitive enzyme‐linked immunosorbent assay (Quantikine HS Human IL‐6 Immunoassay; R&D Systems, Minneapolis, MN) (analytical CV 6.3%).39 Serum fibrinogen was measured by immunoprecipitation using the BNII nephelometer (N‐Antiserum to Human Fibrinogen; Dade Behring) (intra‐assay and interassay CV as 2.7% and 2.6%, respectively). We evaluated inflammation markers as continuous. We also categorized hsCRP ≥2 mg/L as suggested in a previous study.40
Jones M.R., Magid H.S., Al‐Rifai M., McEvoy J.W., Kaufman J.D., Hinckley Stukovsky K.D., Szklo M., Polak J., Burke G.L., Post W.S., Blaha M.J, & Navas‐Acien A. (2016). Secondhand Smoke Exposure and Subclinical Cardiovascular Disease: The Multi‐Ethnic Study of Atherosclerosis. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 5(12), e002965.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!